Figure 2From: Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patientsMass spectra resulting from MALDI-TOF-MS after immunoprecipitation of TTR in plasma (A) and ascites (B) obtained from women with ovarian cancer. The untreated TTR (I) and the TTR after treatment with dithioretiol (II) are shown.Back to article page